DHEA AND KETOCONAZOLE

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。本研究由两部分组成。第一阶段确定患有进展性慢性肾脏疾病的患者，尽管采取了最佳的保守治疗，包括使用适当的血压控制和低蛋白质、氨基酸补充的饮食。在第二阶段，尽管采取了这些措施，但肾功能进行性下降的患者接受酮康唑200毫克/天加小剂量泼尼松(2.5毫克/天)的治疗。目前，两名患有胰岛素依赖型糖尿病和肾病的患者继续接受酮康唑联合泼尼松治疗，并维持独立的肾功能。在研究的第一阶段，6名患者继续接受跟踪，并继续显示出稳定的肾功能。另有三名新患者进入第一阶段。一名患者在最初评估时患有非常严重的肾功能衰竭，并迅速进展到透析。另外两名患者目前正在接受追踪，以评估他们肾衰竭的进展程度。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study has 2 components. Phase 1 identifies patients who have progressive chronic kidney disease despite optimal conservative management including the use of adequate blood pressure control and a low protein, amino acid supplemented diet. In phase 2 those patients with a progressive decrease in kidney function despite these measures are treated with 200 mg/day of ketoconazole plus low dose prednisone (2.5 mg/day). Currently two patients with insulin-dependent diabetes mellitus and nephropathy continue to receive ketoconazole plus prednisone and maintain independent renal function. Six patients continue to be followed in phase 1 of the study and continue to show stable renal function. Three additional new patients were entered into Phase 1. One had very advanced kidney failure at the time of initial assessment and rapidly progressed to dialysis. The other two are currently being followed to assess the degree of progression of their kidney failure.